The trajectory of companies tied to Viagra's legacy presents a intricate investment scenario . While the initial success generated substantial profits , generic alternatives have significantly diminished market share . Investing in associated pharmaceutical businesses now requires a thorough assessment of intellectual property rights , evolving hea